First Clinical Safety Study Starts For Newron's Evenamide

Phase III Expected To Start In 2021 For The Potential Add-On Schizophrenia Therapy

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.